Evidence map›Paper›PMID 32376099›Full record

ReviewMayo Clinic proceedings2020

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Fabian Sanchis-Gomar, Carl J Lavie, Carme Perez-Quilis, Brandon M Henry, Giuseppe Lippi

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04510662 (Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19), which is not on this map. Cited by 91 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04510662 phase2completednot on this map

Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19

TypeinterventionalSponsorAbraham Edgar Gracia-RamosRan2020 to 2021Enrolled66ConditionsCOVID-19, Respiratory Insufficiency, Telmisartan, Respiratory Distress Syndrome, AdultArmsTelmisartan
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  15. Review
  16. Review
  17. Association of ACE2 Gene Variants with the Severity of COVID-19 Disease-A Prospective Observational Study.International journal of environmental research and public health · 2022
    Observational
  18. Review
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Fabian Sanchis-GomarDepartment of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA. Electronic address: fabian.sanchis@uv.es.
Carl J LavieJohn Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA.
Carme Perez-QuilisDepartment of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain.
Brandon M HenryCardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center, OH.
Giuseppe LippiSection of Clinical Biochemistry, University of Verona, Italy.
Universitat de València · ESCincinnati Children's Hospital Medical Center · USOchsner Medical Center · USUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.

Indexed as

Coronavirus InfectionsHypertensionPandemicsPneumonia, ViralAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBetacoronavirusComorbidityCOVID-19HumansPatient SelectionPeptidyl-Dipeptidase ARenin-Angiotensin SystemSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsPeptidyl-Dipeptidase A

Identifiers

PMID32376099
PMCPMC7129862
OpenAlexW3014504275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.